305 related articles for article (PubMed ID: 30885237)
1. A selective c-Met and Trks inhibitor Indo5 suppresses hepatocellular carcinoma growth.
Luo T; Zhang SG; Zhu LF; Zhang FX; Li W; Zhao K; Wen XX; Yu M; Zhan YQ; Chen H; Ge CH; Gao HY; Wang L; Yang XM; Li CY
J Exp Clin Cancer Res; 2019 Mar; 38(1):130. PubMed ID: 30885237
[TBL] [Abstract][Full Text] [Related]
2. ψ-Bufarenogin, a novel anti-tumor compound, suppresses liver cancer growth by inhibiting receptor tyrosine kinase-mediated signaling.
Ding J; Wen W; Xiang D; Yin P; Liu Y; Liu C; He G; Cheng Z; Yin J; Sheng C; Zhang W; Nan F; Ye W; Zhang X; Wang H
Oncotarget; 2015 May; 6(13):11627-39. PubMed ID: 25890498
[TBL] [Abstract][Full Text] [Related]
3. Preclinical trials for prevention of tumor progression of hepatocellular carcinoma by LZ-8 targeting c-Met dependent and independent pathways.
Wu JR; Hu CT; You RI; Ma PL; Pan SM; Lee MC; Wu WS
PLoS One; 2015; 10(1):e0114495. PubMed ID: 25607934
[TBL] [Abstract][Full Text] [Related]
4. Preparation of a Novel One-Armed Anti-c-Met Antibody with Antitumor Activity Against Hepatocellular Carcinoma.
Yin Y; Guo J; Teng F; Yu L; Jiang Y; Xie K; Jiang M; Fang J
Drug Des Devel Ther; 2019; 13():4173-4184. PubMed ID: 31849449
[TBL] [Abstract][Full Text] [Related]
5. CYP1A2 suppresses hepatocellular carcinoma through antagonizing HGF/MET signaling.
Yu J; Xia X; Dong Y; Gong Z; Li G; Chen GG; Lai PBS
Theranostics; 2021; 11(5):2123-2136. PubMed ID: 33500715
[No Abstract] [Full Text] [Related]
6. Targeting FGFR Pathway in Human Hepatocellular Carcinoma: Expressing pFGFR and pMET for Antitumor Activity.
Jo JC; Choi EK; Shin JS; Moon JH; Hong SW; Lee HR; Kim SM; Jung SA; Lee DH; Jung SH; Lee SH; Kim JE; Kim KP; Hong YS; Suh YA; Jang SJ; Choi EK; Lee JS; Jin DH; Kim TW
Mol Cancer Ther; 2015 Nov; 14(11):2613-22. PubMed ID: 26351320
[TBL] [Abstract][Full Text] [Related]
7. Alpelisib combination treatment as novel targeted therapy against hepatocellular carcinoma.
Xu H; Chen K; Shang R; Chen X; Zhang Y; Song X; Evert M; Zhong S; Li B; Calvisi DF; Chen X
Cell Death Dis; 2021 Oct; 12(10):920. PubMed ID: 34625531
[TBL] [Abstract][Full Text] [Related]
8. Chinese herbal formula QHF inhibits hepatocellular carcinoma metastasis via HGF/c-Met signaling pathway.
Yuan S; Gong Y; Chen R; Du J; Zhang H; Chen T
Biomed Pharmacother; 2020 Dec; 132():110867. PubMed ID: 33075668
[TBL] [Abstract][Full Text] [Related]
9. The EGFR/ErbB3 Pathway Acts as a Compensatory Survival Mechanism upon c-Met Inhibition in Human c-Met+ Hepatocellular Carcinoma.
Steinway SN; Dang H; You H; Rountree CB; Ding W
PLoS One; 2015; 10(5):e0128159. PubMed ID: 26000702
[TBL] [Abstract][Full Text] [Related]
10. The dual blockade of MET and VEGFR2 signaling demonstrates pronounced inhibition on tumor growth and metastasis of hepatocellular carcinoma.
Zhang Y; Gao X; Zhu Y; Kadel D; Sun H; Chen J; Luo Q; Sun H; Yang L; Yang J; Sheng Y; Zheng Y; Zhu K; Dong Q; Qin L
J Exp Clin Cancer Res; 2018 Apr; 37(1):93. PubMed ID: 29712569
[TBL] [Abstract][Full Text] [Related]
11. IFI44L is a novel tumor suppressor in human hepatocellular carcinoma affecting cancer stemness, metastasis, and drug resistance via regulating met/Src signaling pathway.
Huang WC; Tung SL; Chen YL; Chen PM; Chu PY
BMC Cancer; 2018 May; 18(1):609. PubMed ID: 29848298
[TBL] [Abstract][Full Text] [Related]
12. ABL1, Overexpressed in Hepatocellular Carcinomas, Regulates Expression of NOTCH1 and Promotes Development of Liver Tumors in Mice.
Wang F; Hou W; Chitsike L; Xu Y; Bettler C; Perera A; Bank T; Cotler SJ; Dhanarajan A; Denning MF; Ding X; Breslin P; Qiang W; Li J; Koleske AJ; Qiu W
Gastroenterology; 2020 Jul; 159(1):289-305.e16. PubMed ID: 32171747
[TBL] [Abstract][Full Text] [Related]
13. The Effect of Selective c-MET Inhibitor on Hepatocellular Carcinoma in the MET-Active, β-Catenin-Mutated Mouse Model.
Zhan N; Michael AA; Wu K; Zeng G; Bell A; Tao J; Monga SP
Gene Expr; 2018 May; 18(2):135-147. PubMed ID: 29409568
[TBL] [Abstract][Full Text] [Related]
14. Resveratrol suppresses human hepatocellular carcinoma via targeting HGF-c-Met signaling pathway.
Gao F; Deng G; Liu W; Zhou K; Li M
Oncol Rep; 2017 Feb; 37(2):1203-1211. PubMed ID: 28075467
[TBL] [Abstract][Full Text] [Related]
15. Dual inhibition of Akt and c-Met as a second-line therapy following acquired resistance to sorafenib in hepatocellular carcinoma cells.
Han P; Li H; Jiang X; Zhai B; Tan G; Zhao D; Qiao H; Liu B; Jiang H; Sun X
Mol Oncol; 2017 Mar; 11(3):320-334. PubMed ID: 28164434
[TBL] [Abstract][Full Text] [Related]
16. Preclinical Evaluation of AMG 337, a Highly Selective Small Molecule MET Inhibitor, in Hepatocellular Carcinoma.
Du Z; Caenepeel S; Shen Y; Rex K; Zhang Y; He Y; Tang ET; Wang O; Zhong W; Zhou H; Huang J; Huang E; Hu L; Coxon A; Zhang M
Mol Cancer Ther; 2016 Jun; 15(6):1227-37. PubMed ID: 27196749
[TBL] [Abstract][Full Text] [Related]
17. MicroRNA-449a suppresses hepatocellular carcinoma cell growth via G1 phase arrest and the HGF/MET c-Met pathway.
Cheng J; Wu LM; Deng XS; Wu J; Lv Z; Zhao HF; Yang Z; Ni Y
Hepatobiliary Pancreat Dis Int; 2018 Aug; 17(4):336-344. PubMed ID: 30108016
[TBL] [Abstract][Full Text] [Related]
18. IGF2 Is Up-regulated by Epigenetic Mechanisms in Hepatocellular Carcinomas and Is an Actionable Oncogene Product in Experimental Models.
Martinez-Quetglas I; Pinyol R; Dauch D; Torrecilla S; Tovar V; Moeini A; Alsinet C; Portela A; Rodriguez-Carunchio L; Solé M; Lujambio A; Villanueva A; Thung S; Esteller M; Zender L; Llovet JM
Gastroenterology; 2016 Dec; 151(6):1192-1205. PubMed ID: 27614046
[TBL] [Abstract][Full Text] [Related]
19. Updates on the hepatocyte growth factor/c-Met axis in hepatocellular carcinoma and its therapeutic implications.
García-Vilas JA; Medina MÁ
World J Gastroenterol; 2018 Sep; 24(33):3695-3708. PubMed ID: 30197476
[TBL] [Abstract][Full Text] [Related]
20. Tivantinib induces G2/M arrest and apoptosis by disrupting tubulin polymerization in hepatocellular carcinoma.
Xiang Q; Zhen Z; Deng DY; Wang J; Chen Y; Li J; Zhang Y; Wang F; Chen N; Chen H; Chen Y
J Exp Clin Cancer Res; 2015 Oct; 34():118. PubMed ID: 26458953
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]